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Introduction 
The introduction of thalidomide in the treatment of multi-
ple myeloma (MM) has improved patients’ outcome.1 Six ran-
domized, phase 3 studies have compared the association of
melphalan-prednisone-thalidomide (MPT) with standard mel-
phalan-prednisone (MP) in patients with newly diagnosed
MM.2-8 A recent meta-analysis of data from individual patients
in these six trials found that the addition of thalidomide to
MP increases the median overall survival by approximately
6.6 months (HR 0.83, 95% CI 0.73-0.94), and the median pro-
gression-free survival by 5.4 months (HR 0.68, 95% CI 0.61-
0.76).9 Based on the results of all these trials, MPT is now con-
sidered a standard first-line treatment for elderly MM
patients, or those ineligible for high-dose therapy. However,
MPT is also a less safe treatment than MP and the lack of reli-
able estimates of the risk and the severity of hematologic and
non-hematologic adverse events and of their impact on clini-
cal outcomes represents an area of uncertainty in clinical prac-
tice. Frequencies of grade 3-4 adverse events varied signifi-
cantly among studies because of the heterogeneity of treat-
ment policies, study designs, the inclusion criteria for patients,
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Treatment with melphalan-prednisone-thalidomide improves the outcome of patients with multiple myeloma and
is now considered a standard of care for patients not eligible for transplantation. However, this treatment is a
major source of morbidity. A meta-analysis of data from individual patients (n=1680) in six randomized trials was
performed, comparing the effects of melphalan-prednisone-thalidomide versus melphalan-prednisone. The main
objective was to estimate the risk of serious adverse events and their impact on outcome. The primary endpoints
were the 2-year cumulative incidence of grade 3-4 hematologic and non-hematologic toxicities. At least 75% of
the grade 3-4 toxicities occurred during the first 6 months of treatment in both treatment groups. The cumulative
incidence of grade 3-4 hematologic toxicities was higher in the melphalan-prednisone-thalidomide group than in
the melphalan-prednisone group (28% versus 22%; HR 1.32, 95% CI 1.05-1.66) as was the cumulative incidence
of non-hematologic toxicities (39% versus 17%, HR 2.78, 95% CI 2.21-3.50). Grade 3-4 non-hematologic toxicities
were significantly increased in patients with poor Performance Status. Occurrence of grade 3-4 non-hematologic
toxicities had a negative impact on both progression-free survival (HR 1.24, 95% CI 1.07-1.45) and overall survival,
(HR 1.23, 95% CI 1.03-1.47). Besides toxicities, progression-free and overall survival were also negatively affected
by advanced International Staging System stage, high creatinine levels and poor Performance Status. Age had a
negative impact on survival as well. Although melphalan-prednisone-thalidomide improved outcome, it increased
toxicities, especially non-hematologic ones. Serious non-hematologic toxicities, older age, poor Performance
Status, and high creatinine levels negatively affected survival.
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data collection and reporting. The most frequent non-
hematologic adverse events in MPT-treated patients in the
six trials were infections (10-28%), peripheral neuropathy
(2-23%), venous thromboembolism (3-12%) and constipa-
tion (3-10%).2-8
In elderly patients, treatment-related adverse events are
a major cause of drug discontinuation and reduced dose-
intensity, thus limiting treatment efficacy. Several studies
have reported a negative impact of treatment-related
adverse events on survival for elderly patients treated with
more aggressive therapies.10-12 In a randomized study, the
overall survival of elderly patients receiving thalidomide-
dexamethasone was significantly shorter than that of
those receiving MP (41.5 versus 49.4 months; P=0.024).
The number of deaths from non-myeloma-related causes
was twice as high in the group treated with thalidomide-
dexamethasone group than in the group treated with MP.10
In another randomized study, overall survival was
decreased in patients receiving lenalidomide plus high-
dose dexamethasone in comparison with those receiving
lenalidomide plus low-dose dexamethasone. Higher rates
of toxicities, treatment discontinuation and early mortality
were reported in patients receiving high-dose dexametha-
sone.11 In a recent phase 3 trial, non-hematologic grade 3-
4 adverse events were reported in 51% of patients who
received bortezomib twice-weekly and 35% of patients
who received bortezomib once-weekly (P=0.003); 15% of
patients in the group treated with twice weekly borte-
zomib and 5% in the group treated with once weekly
bortezomib discontinued therapy (P<0.001). Long-term
outcomes were similar in the two groups. These results
suggest that preventing severe toxicities is essential to
reduce treatment discontinuation and consequently maxi-
mize efficacy.13
We performed a meta-analysis of data from individual
patients in six randomized phase III trials that compared
MPT and MP in elderly patients with MM. We aimed to
provide a reliable estimate of the cumulative incidence of
severe toxicities and of their impact on clinical outcomes.
This safety analysis is part of a project agreed upon by the
principal investigators of the six trials; an efficacy meta-
analysis with the same studies and criteria has been pub-
lished recently.9
Design and Methods
Objectives
The primary objective was to compare the risk of devel-
oping grade 3-4 hematologic and non-hematologic
adverse events during the first 2 years of treatment with
MPT or MP.
Secondary objectives were: (i) to analyze the role of
patients’ characteristics on the risk of grade 3-4 adverse
events; (ii) to assess the impact of the occurrence of grade
3-4 adverse events on progression-free and overall sur-
vival; (iii) to explore the safety profile of MPT versusMP in
subgroups of patients stratified by age, gender, Durie and
Salmon (DS) stage, International Staging System (ISS)
stage, World Health Organization Performance Status
(WHO-PS) and serum creatinine.
Data source and search
At the beginning of 2011, the principal investigators of the six
MPT trials completed within the European Myeloma Network
agreed to perform an individual patient data meta-analysis and
provided the safety data of their respective trials. An efficacy
analysis, based on the same criteria, has already been performed
and published under the coordination of the Nordic Myeloma
Study Group.9 To verify the completeness of the studies included
in this project, we carried out a MEDLINE search using the terms
melphalan, prednisone, thalidomide, multiple myeloma, elderly
patients. In total, we found 73 original full papers in English, pub-
lished between January 2000 to January 2011. There were seven
articles providing a direct comparison between the old standard
MP and the new standard MPT in randomized phase 3 studies,
one of which was an update of a previously published analysis,
confirming the completeness of our data. To assess the likelihood
of bias of each study, two authors independently reviewed the
original articles using the Jadad scale.14 The score associated with
each study is reported in Table 1.
Data extraction
From 2000 onwards, six randomized phase 3 trials comparing
MPT versusMP in newly diagnosed MM patients were completed
by five groups in Europe and Turkey [Gruppo Italiano Malattie
EMatologiche dell’Adulto (GIMEMA), Dutch-Belgium Hemato-
Oncology Cooperative Group (HOVON), Intergroupe Francophone
du Myelome (IFM), Nordic Myeloma Study Group (NMSG), and
Turkish Myeloma Study Group (TMSG)]. These studies were
approved by the respective institutional review boards at each of
the participating centers. Individual patients’ data were collected
by investigators for each patient enrolled at each coordinating cen-
ter. The main inclusion criteria and planned treatment schedule of
the six randomized controlled trials, described in detail else-
where,2-8 are summarized in Table 1. The characteristics of
patients selected (WHO-PS, stage of disease and age range), study
design and treatment policy (dose and the number of cycles/dura-
tion of thalidomide and MP) were different among the studies.
The following data available across all studies were collected for
each patient: baseline data, including age, creatinine levels, WHO-
PS, ISS stage,15 DS stage;16 date of progression/last known remis-
sion, date of death/date last known to be alive; grade, type and
date of adverse events. All adverse event data were defined and
graded according to the National Cancer Institute’s Common
Terminology Criteria for Adverse Events (version 3.0).17 Toxic
deaths were defined as deaths related to treatment and were
assessed by investigators. Adverse events were systematically
reviewed for consistency and completeness by the central coordi-
nating center and any problem was discussed and resolved by con-
tacting the study investigators.
Statistical analysis 
All 1680 (out of 1685) patients who could be evaluated for tox-
icity were included in the analysis. Descriptive statistics were used
to summarize the frequency of adverse events, deaths and treat-
ment discontinuation. In the case of multiple grade 3-4 hematolog-
ic or grade 3-4 non-hematologic adverse events we considered
only the first event for each type of toxicity. Patients who experi-
enced the same type of toxicity more than once were counted
only once. We described baseline patients’ characteristics and
study endpoints according to treatment (pooled analysis of all
patients treated with MPT versusMP) and according to study.   
Progression-free survival was calculated from the time of ran-
domization until the date of progression, relapse, death from any
cause, or the date the patient was last known to be in remission.
Overall survival was calculated from the time of randomization
until the date of death or the date the patient was last known to be
alive. 
We performed a competing risk analysis on the incidence of
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adverse events, either grade 3-4 hematologic or grade 3-4 non-
hematologic, with the competing events defined as progression or
death. We used a proportional hazard frailty model for the subdis-
tribution to analyze the effect of baseline factors (age, sex, WHO-
PS, ISS and DS stages, creatinine level) on the cumulative inci-
dence function of toxicity, incorporating heterogeneity across
studies.18
The effects of grade 3-4 hematologic or grade 3-4 non-hemato-
logic adverse events on progression-free survival and overall sur-
vival were estimated with Cox models, with frailty shared within
study and assumed to be Gamma distributed across studies,19
adjusting for baseline factors and treatment, and treating grade 3-
4 hematologic and grade 3-4 non-hematologic adverse events as
time-dependent variables.
In these analyses, the time of adverse event occurrence was cen-
sored at 2 years after the start of treatment. Data from the IFM-I
study were excluded from all time-to-event analyses since the
time of toxicity onset was not recorded for the majority of
patients. All analyses were performed using the 'cmprsk' and
‘coxme’ packages of R software.
Results
Patients’ characteristics 
A total of 1680 patients were analyzed: 807 received
MPT and 873 received MP. Overall, baseline demographic
and disease characteristics were equally distributed in the
two treatment groups (Table 2). The median age was 71-
74 years in all studies, with the exception of the IFM-I
study (69 years) in which patients older than 75 years
were excluded, and the IFM-II study (78 years) in which
patients younger than 75 years were excluded. The pro-
portion of patients with WHO-PS 3-4 was 4-8% in all
studies, except the NMSG trial in which it was 33%. The
frequency of ISS stage III at diagnosis was higher in the
NMSG and TMSG trials.
Grade 3-4 hematologic and non-hematologic 
adverse events
The frequency of toxic deaths was 6% among patients
treated with MPT and 7% in those treated with MP. The
most common causes of toxic death were infections (3%
for MPT and 4% for MP) and cardiovascular adverse
events, including thromboembolic events, pulmonary
edema, cardiac events and stroke (2% in both the MPT
and MP groups). The raw frequency of toxic deaths varied
between trials: it was 1% in the IFM-II and HOVON trials
but 10-11% in the GIMEMA and IFM-I studies, which had
less stringent inclusion criteria. 
The proportions of patients who developed at least one
grade 3-4 hematologic adverse event were 32% and 29%
in the MPT and MP groups, respectively. Grade 3-4 non-
hematologic adverse events were more frequent in MPT
patients (40%) than in MP patients (18%) (Table 3). The
most common grade 3-4 non-hematologic adverse event
was infection (13% for MPT versus 9% for MP). Other
adverse events, more common among MPT patients than
MP patients, were peripheral/central neuropathy (15%
versus 3%), deep vein thrombosis (6% versus 2%), and der-
matological toxicity (3% versus 1%). Gastrointestinal
events, pulmonary embolism and cardiac toxicities were
less frequent and similarly distributed between the two
groups. Overall, toxicity-related discontinuation of
thalidomide was reported in 35% of MPT patients: neu-
ropathy was the main reason (15%), followed by infec-
tions (3%), venous thromboembolism (3%), dermatologi-
cal toxicity (3%) and cardiac toxicities (3%). Melphalan
discontinuation was reported in 5% of MPT and MP
patients and was mainly caused by hematologic toxicities. 
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Table 1. Characteristics of the six randomized trials.
Acronym GIMEMA HOVON IFM-I IFM-II NMSG TMSG
Age, years >65 >65 65-75 ≥75 >65 >55
WHO PS 0-4 0-3 0-4 0-4 0-4 0-2
Melphalan 4 mg/sqm 0.25 mg/kg 0.25 mg/kg 0.20  mg/kg 0.25 mg/kg 9 mg/sqm 
days 1–7 days 1–5 days 1–4 days 1–4 days 1–4 days 1–4
Prednisone 40 mg/sqm 1 mg/kg 2 mg/kg 2 mg/kg 100 mg 60 mg/sqm
days 1–7 days 1–5 days 1–4 days 1–4 days 1–4 days 1–4
N. of cycles / interval 6 cy/ 4 wks 8 cy/ 4 wks 12 cy/ 6 wks 12 cy/ 6 wks Until plateau/6wks 8 cy/ 6 wks
Total duration of induction (weeks) 24 32 72 72 32∞ 48
Thalidomide mg/day 100 200 100–400 100 200–400 100
Duration Until relapse 8 cy, 12 cy 12 cy until relapse 8 cy
followed by 50 mg 
until relapse
Cumulative melphalan dose ITT* 319 mg 750 mg 900 mg 720 mg 400 mg∞ 550 mg
Melphalan dose intensity ITT 13 mg/wk 23 mg/wk 13 mg/wk 10 mg/Kg 12 mg/wk∞ 11 mg/wk
Cumulative thalidomide dose ITT 29000 mg§ 46000 mg§ 101000 mg^ 50000 mg 47000 mg^§ 34000 mg
Thalidomide dose intensity ITT 800 mg/wk§ 1300 mg/wk§ 1400 mg/wk^ 700 mg/wk 1500 mg/wk^§ 700 mg/wk
Randomized to MPT (n.) 167 165 125 113 179 58
Randomized to MP (n.) 164 168 196 116 172 57
JADAD score 3 2 2 3 4 2
GIMEMA: Gruppo Italiano Malattie EMatologiche dell’Adulto; HOVON: Dutch-Belgium Hemato-Oncology Cooperative Group; IFM: Intergroupe Francophone du Myelome; NMSG:
Nordic Myeloma Study Group;  TMSG: Turkish Myeloma Study Group; WHO PS= World Health Organization Performance Status;  mg: milligram; sqm: square meter; Kg: Kilogram; cy:
cycles; wks: weeks; NA: not available; ITT: intention to treat; ∞calculated on the median number of cycles; *calculated assuming the patient’s weight was 75 Kg,  height 1.80 m, body
surface area 1.9 sqm; ^calculated on the median thalidomide dose; §calculated on the median duration of thalidomide treatment.
Toxicities differed between trials (Table 3). Patients
enrolled in the HOVON and IFM-I studies, who received
the highest dose of melphalan, reported a higher propor-
tion of grade 3-4 hematologic toxicity compared with
patients in the four other trials. The highest incidences of
non-hematologic adverse events were reported in the
GIMEMA, HOVON, NSMG and TMSG trials probably
because of the higher number of patients with creatinine
levels ≥176 μmol/L and/or higher thalidomide doses.
Infections were more frequent in the HOVON trial, in
which there was also a higher incidence of hematologic
toxicity. The incidence of neurological toxicity was higher
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Table 2. Baseline characteristics of patients included in the safety meta-analysis, according to treatments (pooled data) and according to trial
(MPT+MP).
MPT MP GIMEMA HOVON IFM-I IFM-II NMSG TMSG
(N=807) (N=873) (N=331) (N=333) (N=321) (N=229) (N=351) (N=115)
Age (median, years) 73 73 73 73 69 79 74 71
≥75 323 (40) 336 (39) 110 (33) 121 (36) 6 (2) 227 (99) 159 (45) 36 (31)
Gender  n. (%)
Male 414 (51) 491 (56) 179 (54) 186 (56) 172 (54) 104 (45) 202 (58) 62 (54)
Female 393 (49) 382 (44) 152 (46) 147 (44) 149 (46) 125 (55) 153 (42) 53 (46)
ISS stage n. (%)*
1 159 (24) 190 (26) 64 (24) 47 (21) 99 (34) 63 (31) 56 (18) 20 (19)
2 290 (43) 315 (43) 125 (47) 115 (51) 109 (37) 76 (37) 139 (45) 41 (39)
3 223 (33) 227 (31) 75 (28) 63 (28) 86 (29) 67 (33) 116 (37) 43 (41)
NA 135 141 67 108 27 23 40 11
WHO PS n. (%)*
0 231 (29) 242 (28) 171 (52) 121 (36) 76 (24) 44 (19) 53 (17) 8 (7)
1 286 (36) 335 (39) 80 (24) 154 (46) 160 (50) 104 (45) 74 (23) 49 (43)
2 182 (23) 191 (22) 62 (19) 45 (14) 61 (19) 65 (28) 87 (27) 53 (46)
3 68 (9) 80 (9) 16 (5) 13 (4) 18 (6) 15 (7) 82 (26) 4 (4)
4 18 (2) 13 (2) 2 (1) 0 5 (2) 1 (0.4) 23 (7) 0 (0)
NA 22 12 0 0 1 0 32 1
DS stage n.(%)*
I 54 (7) 59 (7) 0 1(0.3) 31 (10) 21 (9) 54 (16) 6 (5)
II 264 (33) 268 (31) 125 (38) 85 (26) 83 (26) 52 (23) 127 (38) 60 (53)
III 483 (60) 534 (62) 206 (62) 247 (74) 206 (64) 155 (68) 156 (46) 47 (42)
NA 6 12 0 0 1 1 14 2
Creatinine 88 88 71 96 93 90 95 97
(median, μmol/L)
>176 μmol/L N(%) 93 (12) 81 (9) 24 (7) 39 (12) 24 (7) 16 (7) 50 (14) 20 (17)
MPT: melphalan-prednisone-thalidomide; MP: melphalan-prednisone; GIMEMA: Gruppo Italiano Malattie EMatologiche dell’Adulto; HOVON: Dutch-Belgium Hemato-Oncology
Cooperative Group; IFM: Intergroupe Francophone du Myelome; NMSG: Nordic Myeloma Study Group;  TMSG: Turkish Myeloma Study Group; WHO PS= World Health Organization
Performance Status; N: number; NA: not available; ISS: International Staging System; μmol/L: micromole/liter;*% calculated on number of patients whose data were available; per-
centage may not total 100 because of rounding.
Figure 1. (A) Cumulative incidences of grade 3-4 hematologic adverse events and cumulative incidences of progression or death without
adverse events in melphalan-prednisone-thalidomide (MPT) and melphalan-prednisone (MP) treated patients. (B)  Cumulative incidences of
grade 3-4 non-hematologic adverse events and cumulative incidences of progression or death without adverse events in MPT and MP treated
patients.
A BHematologic adverse events
Non-Hematologic adverse events
0 3 6 9 12 15 18 21 24
Months after randomization
MP:
MPT:
grade 3-4 adverse events
grade 3-4 adverse events
progression/death
progression/death
2 year: 28%
(95% CI:25-31%)
(95% CI:35-43%)
2 year: 39%
MP:
MPT:
grade 3-4 adverse events
2 year: 22%
(95% CI: 19-25%)
2 year: 17%
(95% CI: 14-20%)
grade 3-4 adverse events
progression/death
progression/death
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Cu
m
ul
at
iv
e 
in
ci
de
nc
e
Cu
m
ul
at
iv
e 
in
ci
de
nc
e
0 3 6 9 12 15 18 21 24
Months after randomization
in the GIMEMA, HOVON and NMSG trials with thalido-
mide maintenance after induction and in the IFM-II trial,
which included older patients. In the GIMEMA study, the
incidence of thrombotic events decreased significantly
after the introduction of prophylactic anticoagulation.2,3
Cardiac toxicity was less frequent in the IFM-I trial, which
only included patients younger than 75 years.
The cumulative incidences of grade 3-4 hematologic
(Figure 1A) and non-hematologic adverse events (Figure
1B) in the patients treated with MPT or MP have been
plotted along with the cumulative incidences of the com-
peting events (disease progression or deaths without grade
3-4 adverse events). Eighty percent of grade 3-4 hemato-
logic adverse events occurred within the first 6 months of
treatment in both groups. The cumulative incidence of
grade 3-4 hematologic adverse events slowly increased
with time in both groups and at 2 years was slightly high-
er in MPT patients than in MP patients (28% versus 22%;
Gray test P=0.023). 
Seventy-five percent of grade 3-4 non-hematologic
adverse events occurred in the first 6 months of therapy in
both groups. The cumulative incidence of grade 3-4 non-
hematologic adverse events was significantly higher in the
MPT group (39% at 2 years) than in the MP group (17%
at 2 years), (Gray test P<0.0001). 
In a multivariable model, including several baseline
characteristics, the risk of developing a grade 3-4 hemato-
logic adverse event was higher among females (HR 1.48,
95% CI 1.18-1.85; P=0.001) and patients randomized to
MPT treatment (HR 1.32, 95% CI 1.05-1.66; P=0.016)
(Table 4). The risk of grade 3-4 non-hematologic adverse
events was strongly increased by MPT treatment (HR
2.78, 95%CI 2.21-3.50; P=0.000) and by WHO-PS score
(HR 1.18 per point, 95% CI 1.06-1.32, P=0.003).
An exploratory subgroup analysis, considering age, gen-
der, ISS stage, WHO-PS and serum creatinine, did not find
any important effect modifier of the increased risk of MPT
for grade 3-4 hematologic and non-hematologic adverse
events.
Impact of treatment-related adverse events 
on clinical outcomes
Progression-free survival was negatively influenced by
the occurrence of a non-hematologic adverse event (HR
1.24, 95% CI 1.07-1.45; P=0.006) but not by hematologic
adverse events. Other risk factors for progression-free sur-
vival were poor WHO-PS, high creatinine and more
advanced ISS myeloma stage (Table 5).
The occurrence of non-hematologic adverse events was
also associated with a worse overall survival (HR 1.23,
95% CI 1.03-1.47; P=0.024). Other baseline factors associ-
ated with shorter overall survival were age ≥75 years (HR
1.18, 95% CI 1.01-1.38), WHO-PS (HR 1.29 per point,
95% CI 1.20-1.39), creatinine levels ≥ 176 μmol/L (HR
1.66, 95% CI 1.31-2.10) and advanced ISS stage (ISS 3 ver-
sus 1: HR 2.05, 95% CI 1.57-2.67; ISS 2 versus 1: HR 1.59,
95% CI 1.24-2.03) (Table 5).
After accounting for baseline characteristics and despite
the increased occurrence of adverse events, patients ran-
domized to MPT showed a better progression-free sur-
vival (HR 0.68, 95% CI 0.60- 0.78; P<0.0001) and overall
survival (HR 0.82, 95% CI 0.70-0.86; P=0.014).
In all the fitted models the point estimate of the frailty
variance was not statistically significant, indicating a low
heterogeneity between studies when most important
patients’ characteristics were included in the models.
Discussion
Six randomized, phase 3 studies compared the associa-
tion of MPT with standard MP as first-line treatment in
elderly MM patients. A meta-analysis of efficacy data of
these trials showed a clear overall survival and progres-
sion-free survival benefit for patients receiving thalido-
mide.9 In the present meta-analysis, data from the individ-
ual patients enrolled in the same six trials were pooled and
safety data were analyzed. Although the results showed
an increased incidence of toxic events, especially non-
hematologic, in patients treated with MPT, the benefit of
adding thalidomide to MP was clearly confirmed. 
In the pooled analysis, the rate of toxic deaths was
similar in both MPT and MP patients. In a previous meta-
analysis of 27 randomized trials comparing MP with
combination chemotherapies, overall survival was
unchanged but the incidence of toxic deaths was higher
among the patients treated with combination
chemotherapy.20 Similarly, for the same reason, dexam-
ethasone-based regimens did not improve survival com-
pared with MP.21
The cumulative incidence of hematologic grade 3-4
adverse events at 2 years was marginally higher in MPT
Safety profile of thalidomide in elderly MM patients
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Table 3. Frequency of adverse events, either grade 3-4 hematologic or grade 3-4 non-hematologic, according to treatment (pooled data) and
according to trial (MPT+MP).
MPT MP GIMEMA HOVON IFM-I IFM-II NMSG TMSG
(N=807) (N=873) (N=331) (N=333) (N=321) (N=229) (N=351) (N=115)
Grade 3-4 hematologic AE n. (%) 259 (32) 255 (29) 85 (26) 142 (43) 134 (42) 38 (17) 94 (27) 21 (18)
Grade 3-4 non-hematologic AE n. (%) 324 (40) 159 (18) 89 (27) 110 (33) 75 (23) 53 (23) 123 (35) 33 (29)
Infections 112 (13) 70 (9) 22 (7) 68 (20) 33 (10) 9 (4) 33 (9) 17 (15)
Peripheral neuropathy 49 (6) 6 (1) 20 (6) 7 (2) 7 (2) 4 (2) 11 (3) 6 (5)
Neurological except peripheral neuropathy 73 (9) 17 (2) 8 (2) 24 (7) 8 (2) 15 (7) 35 (10) -
Deep vein thrombosis 48 (6) 13 (2) 19 (6) 6 (2) 12 (4) 6 (3) 14 (4) 4 (3)
Pulmonary embolism 22 (3) 17 (2) 4 (1) 3 (1) 11 (3) 4 (2) 14 (4) 3 (3)
Cardiac 50 (6) 30 (4) 21 (6) 4 (3) 2 (1) 15 (7) 21 (6) 5 (4)
Gastrointestinal 47 (5) 32 (4) 9 (3) 3 (3) 19 (6) 5 (2) 25 (7) 5 (4)
MPT: melphalan-prednisone-thalidomide; MP: melphalan-prednisone; GIMEMA: Gruppo Italiano Malattie EMatologiche dell’Adulto; HOVON: Dutch-Belgium Hemato-Oncology
Cooperative Group; IFM: Intergroupe Francophone du Myelome; NMSG: Nordic Myeloma Study Group;  TMSG: Turkish Myeloma Study Group; AE: adverse events; N: number of
patients; §Percentages were calculated on thalidomide-treated patients.
patients than in MP patients (28% versus 22%, adjusted
HR 1.32, 95% CI 1.05-1.66), confirming the low risk of
hematologic toxicity caused by adding thalidomide to
MP.22 As regards baseline patients’ characteristics, the risk
of hematologic toxicity was higher for females.
The 2-year incidence of grade 3-4 non-hematologic
adverse events in MPT patients was more than double
that in MP patients (39% versus 17%, with an adjusted HR
of 2.78, 95% CI 2.21-3.50). Infections were the most fre-
quent non-hematologic adverse events in both groups;
neuropathy, deep-vein thrombosis, and dermatological
toxicity were the most frequent thalidomide-related
adverse events. The most important risk factor for non-
hematologic toxicity was the WHO-PS, suggesting that
frail patients are at increased risk of severe adverse events,
independently of the specific treatment.
An analysis of the incidence of hematologic toxicities by
trial may suggest a correlation between hematologic toxici-
ty and melphalan doses. The toxicity analyses in each trial
suggest that neuropathy was probably associated with the
duration of thalidomide treatment, whereas cardiac toxici-
ties were likely to be age-related. However, after adjusting
for differences among study protocols and patients’ charac-
teristics, the difference in cumulative incidences of adverse
events between studies was negligible. 
Eighty percent of grade 3-4 hematologic adverse events
and 75% of grade 3-4 non-hematologic adverse events
occurred during the first 6 months of treatment in both the
MPT and MP groups, supporting the need for careful mon-
itoring of treatment-related adverse events during this peri-
od. At least for some avoidable complications, appropriate
prophylactic measures, such as antibiotic prophylaxis to
reduce infections, should be considered to improve safety.
One limitation of our analysis lies in the fact that we
used data from randomized trials only. Patients enrolled in
randomized trials are usually selected subjects, and treat-
ment feasibility may be different when the same schema
is administered to a wider population of patients. Results
from studies other than randomized trials are, therefore,
particularly important. However, the criteria for including
patients in the studies considered were not strict: the
Nordic trial included patients with WHO-PS 0-4, with
30% of patients having WHO-PS 3-4; the Italian study
also included patients with abnormal cardiac, respiratory,
a. Palumbo et al.
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Table 4. Risk factors for grade 3-4 hematologic and non-hematologic adverse events. Hazard ratios (HR) and 95% confidence intervals (95% CI)
from proportional hazard frailty models for competing risks. 
Grade 3-4 hematologic adverse events Grade 3-4 non-hematologic adverse events
HR 95%CI P value HR 95%CI P value
Age ≥ 75 years 0.83 0.65 1.07 0.157 1.10 0.88 1.38 0.412
Gender (female) 1.48 1.18 1.85 0.001 0.98 0.79 1.21 0.827
WHO-PS 0.95 0.83 1.07 0.377 1.18 1.06 1.32 0.003
Creatinine >176 μmol/L 1.16 0.80 1.68 0.445 0.93 0.66 1.31 0.678
ISS stage 2 1.28 0.91 1.80 0.163 0.87 0.64 1.19 0.393
ISS stage 3 1.37 0.94 2.00 0.100 1.30 0.93 1.81 0.125
ISS stage not known 1.01 0.68 1.50 0.961 0.88 0.60 1.27 0.481
DS stage II 1.27 0.75 2.17 0.375 1.65 0.99 2.73 0.053
DS stage III 1.10 0.65 1.86 0.736 1.45 0.88 2.39 0.148
MPT treatment 1.32 1.05 1.66 0.016 2.78 2.21 3.50 0.000
PS: performance status; ISS: International Staging System; DS: Durie-Salmon; MPT: melphalan-prednisone-thalidomide.
Table 5. Influence of baseline patients’ characteristics, MPT treatment and grade 3-4 hematologic and non-hematologic  adverse events on pro-
gression-free survival and overall survival. Hazard ratios (HR) and 95% confidence interval (95% CI) from Cox frailty models.
Progression-free survival Overall survival
HR 95%CI P value HR 95%CI P value
Age ≥ 75 years 0.94 0.82 1.07 0.347 1.18 1.01 1.38 0.032
Gender (female) 1.00 0.88 1.14 0.959 0.91 0.78 1.07 0.253
WHO-PS 1.15 1.08 1.23 0.000 1.29 1.20 1.39 0.000
Creatinine >176 μmol/L 1.33 1.08 1.64 0.007 1.66 1.31 2.10 0.000
ISS stage 2 1.41 1.17 1.70 0.000 1.59 1.24 2.03 0.000
ISS stage 3 1.63 1.32 2.00 0.000 2.05 1.57 2.67 0.000
ISS stage not known 1.36 1.09 1.69 0.006 1.75 1.33 2.30 0.000
DS stage II 1.04 0.77 1.42 0.795 1.05 0.71 1.55 0.805
DS stage III 1.17 0.87 1.58 0.297 1.21 0.83 1.76 0.316
MPT treatment 0.68 0.60 0.78 0.000 0.82 0.70 0.96 0.014
Grade 3-4 hematologic-AE 1.07 0.91 1.26 0.386 1.19 0.99 1.44 0.060
Grade 3-4 non-hematologic AE 1.24 1.07 1.45 0.006 1.23 1.03 1.47 0.024
PS: Performance Status; ISS: International Staging System; DS: Durie-Salmon; MPT: melphalan-prednisone-thalidomide; AE: adverse event.
liver and renal function, and the IFM II trial enrolled
patients over the age of 75 years.
The occurrence of severe complications, especially non-
hematologic toxicities, is detrimental to these patients, not
only because of their direct consequences, but also
because the adverse events often lead to dose reductions
or a premature interruption of treatment. This meta-analy-
sis found that the occurrence of grade 3-4 non-hematolog-
ic adverse events was associated, irrespectively of treat-
ment, with a poor prognosis, in terms of both progression-
free survival (adjusted HR 1.24, 95% CI 1.07-1.45) and
overall survival (adjusted HR 1.23, 95% CI 1.03-1.46).
Other baseline factors were confirmed to be strong predic-
tors of a worse progression-free survival and overall sur-
vival, such as advanced ISS stage, high creatinine levels
and poor WHO-PS. As expected, age had a negative
impact on overall survival.
The adverse prognostic impact of advanced age is prob-
ably multifactorial. Myeloma biology may differ by age at
presentation.23 Moreover, the aging process is associated
with reductions in renal and gastric function, hepatic mass
and blood flow, bone marrow status, and cardiovascular
function.24-26 Poor WHO-PS was one of the most relevant
factors, and it increased the risk of death by 1.29-fold for
each point (95% CI 1.20-1.39). It may represent an indirect
measure of multiple organ dysfunction, frequently present
in elderly patients. Unfortunately, no data on baseline
comorbidities, other than renal failure, were available.
Creatinine ≥ 176 μmol/L did not increase the risk of severe
adverse events, but significantly increased the risk of
death by 1.66-fold (95% CI 1.31-2.10). Thalidomide phar-
macokinetics is not affected by renal impairment and no
dose reduction is required.22 The increased risk of death
seems to be mainly related to the poor prognosis of renal
disease by itself rather than to a toxic effect of thalidomide
on renal function. 
Our analysis clearly showed that the occurrence of
grade 3-4 non-hematologic adverse events is associated
with a worse prognosis, independently of treatment. At
least in part, these adverse events may be related to preex-
isting sub-clinical organ dysfunction that emerges clinical-
ly after MM treatment. The occurrence of serious adverse
events increased the risk of death in both the MPT and MP
groups, suggesting that comorbidity and reduced func-
tional reserves in patients with cancer have a negative
impact on survival, independently of treatment. Thus, it is
important to search for subclinical comorbidities in all eld-
erly patients before starting treatment. The recent efficacy
meta-analysis showed that the benefit of MPT over MP is
limited in patients with high creatinine levels and poor
WHO-PS.9 Our analysis suggests that this lack of benefit
might be related to increased toxicity and to the reduced
treatment efficacy caused by the occurrence of adverse
events. Patients with poor WHO-PS, generally presenting
with co-morbidities, are likely to be at higher risk of devel-
oping adverse events. 
In conclusion, the incidence of severe adverse events,
especially non-hematologic ones, was higher in patients
treated with MPT than in those treated with MP, and their
occurrence had a negative impact on prognosis. However,
patients randomized to MPT showed a better outcome.
Older patients and those with high creatinine levels or poor
WHO-PS status should be carefully considered for more
appropriate treatment choices. In these patients, lower
doses of melphalan (from 0.25 to 0.18 to 0.13 mg/kg) and
thalidomide (from 100 to 50 mg/day, to 50 mg every other
day) have been suggested.27 Personalized therapy, with
appropriate dose adjustments or modified treatment
schema, are needed to improve the balance between bene-
fits and harm of available treatments. Better tolerated regi-
mens are likely to reduce the need for treatment interrup-
tions and thus optimize treatment efficacy. Timely prophy-
lactic interventions and adequate and prompt management
of adverse events are also necessary. Future clinical trials,
with few exclusion criteria, comparing different individual-
ized therapeutic strategies on clinically relevant endpoints,
should be considered a high research priority.28 The results
from such trials will eventually lead to tailored treatment
schema for elderly MM patients, with further improve-
ments in survival, quality of life and cost-effectiveness.
Acknowledgments
We thank the patients who agreed to participate in the studies
analyzed, the nurses, the data manager Federica Leotta and the
editorial assistant Giorgio Schirripa.
Authorship and Disclosures
Information on authorship, contributions, and financial & other
disclosures was provided by the authors and is available with the
online version of this article at www.haematologica.org.
Safety profile of thalidomide in elderly MM patients
haematologica | 2013; 98(1) 93
References
1. Singhal S, Mehta J, Desikan R, Ayers D,
Roberson P, Eddlemon P, et al. Antitumor
activity of thalidomide in refractory multi-
ple myeloma. N Engl J Med. 1999;341(21):
1565-71.
2. Palumbo A, Bringhen S, Caravita T, Merla
E, Capparella V, Callea V, et al. Oral mel-
phalan and prednisone chemotherapy plus
thalidomide compared with melphalan and
prednisone alone in elderly patients with
multiple myeloma: randomised controlled
trial. Lancet. 2006;367(9513):825-31.
3. Palumbo A, Bringhen S, Liberati AM,
Caravita T, Falcone A, Callea V, et al. Oral
melphalan, prednisone, and thalidomide in
elderly patients with multiple myeloma:
updated results of a randomized controlled
trial. Blood. 2008;112(8):3107-14.
4. Facon T, Mary JY, Hulin C, Benboubker L,
Attal M, Pegourie B, et al. Melphalan and
prednisone plus thalidomide versus mel-
phalan and prednisone alone or reduced-
intensity autologous stem cell transplanta-
tion in elderly patients with multiple
myeloma (IFM 99-06): a randomised trial.
Lancet. 2007;370(9594):1209-18.
5. Hulin C, Facon T, Rodon P, Pegourie B,
Benboubker L, Doyen C, et al. Efficacy of
melphalan and prednisone plus thalido-
mide in patients older than 75 years with
newly diagnosed multiple myeloma: IFM
01/01 trial. J Clin Oncol. 2009;27(22):3664-
70.
6. Wijermans P, Schaafsma M, Termorshuizen
F, Ammerlaan R, Wittebol S, Sinnige H, et
al. Phase III study of the value of thalido-
mide added to melphalan plus prednisone
in elderly patients with newly diagnosed
multiple myeloma: The HOVON 49 Study.
J Clin Oncol. 2010;28 (19):3160-6.
7. Waage A, Gimsing P, Fayers P, Abildgaard
N, Ahlberg L, Björkstrand B, et al.
Melphalan and prednisone plus thalido-
mide or placebo in elderly patients with
multiple myeloma. Blood. 2010;116(9):
1405-12.
8. Beksac M, Haznedar R, Firatli-Tuglular T,
Ozdogu H, Aydogdu I, Konuk N, et al.
Addition of thalidomide to oral melpha-
lan/prednisone in patients with multiple
myeloma not eligible for transplantation:
results of a randomized trial from the
Turkish Myeloma Study Group. Eur J
Haematol. 2010;86(1):16-22.
9. Fayers PM, Palumbo A, Hulin C, Waage A,
Wijermans P, Beksaç M, et al. Thalidomide
for previously untreated elderly patients
with multiple myeloma: meta-analysis of
1685 individual patient data from 6 ran-
domized clinical trials. Blood. 2011;118
(5):1239-47.
10. Ludwig H, Hajek R, Tóthová E, Drach J,
Adam Z, Labar B, et al. Thalidomide-dex-
amethasone compared with melphalan-
prednisolone in elderly patients with multi-
ple myeloma. Blood. 2009;113(15):3435-42. 
11. Rajkumar SV, Jacobus S, Callander NS,
Fonseca R, Vesole DH, Williams ME, et al.
Lenalidomide plus high-dose dexametha-
sone versus lenalidomide plus low-dose
dexamethasone as initial therapy for newly
diagnosed multiple myeloma: an open-
label randomised controlled trial. Lancet
Oncol. 2010;11(1):29-37. 
12. Zonder JA, Crowley J, Hussein MA,
Bolejack V, Moore DF Sr, Whittenberger BF,
et al. Lenalidomide and high-dose dexam-
ethasone compared with dexamethasone
as initial therapy for multiple myeloma: a
randomized Southwest Oncology Group
trial (S0232). Blood. 2010;116(26):5838-41. 
13. Bringhen S, Larocca A, Rossi D, Cavalli M,
Genuardi M, Ria R, et al. Efficacy and safe-
ty of once weekly bortezomib in multiple
myeloma patients. Blood. 2010;116(23):
4745-53.
14. Jadad AR, Moore RA, Carroll D, Jenkinson
C, Reynolds DJ, Gavaghan DJ, et al.
Assessing the quality of reports of random-
ized clinical trials: is blinding necessary?
Control Clin Trials. 1996;17(1):1-12.
15.  Greipp PR, San Miguel J, Durie BG, Crowley
JJ, Barlogie B, Bladé J, et al. International
staging system for multiple myeloma. J Clin
Oncol. 2005;23(15):3412-20.
16. Durie BG, Salmon SE. A clinical staging sys-
tem for multiple myeloma: correlation of
measured myeloma cell mass with present-
ing clinical features, response to treatment,
and survival. Cancer. 1975;36(3):842-54.
17.  National Cancer Institute. National Cancer
Institute Cancer Therapy Evaluation
Program Common Terminology Criteria
for Adverse Events, Version 3.0. 9 August
2006. http://
ctep.cancer.gov/protocolDevelopment/elec
tronic_applications/ctc.htm#ctc_30
18. Katsahian S, Resche-Rigon M, Chevret S,
Porcher R. Analysing multicentre compet-
ing risk data with mixed proportional haz-
ards model for the subdistribution. Stat
Med. 2006;25(24):4267-78.
19. Clayton D, Cuzick J. Multivariate generali-
sations of the proportional hazards model
(with discussion). Journal of the Royal
Statistical Society, Series A 1985;148:82-
117.
20. Myeloma Trialists’ Collaborative Group.
Combination chemotherapy versus mel-
phalan and prednisone as treatment for
multiple myeloma: an overview of 6633
patients from 27 randomized trials. J Clin
Oncol. 1998;16(12):3832-42.
21. Facon T, Mary JY, Pégourie B, Attal M,
Renaud M, Sadoun A, et al.
Dexamethasone-based regimens versus
melphalan-prednisone for elderly multiple
myeloma patients ineligible for high-dose
therapy. Blood. 2006;107(4):1292-8.
22. Palumbo A, Facon T, Sonneveld P, Bladè J,
Offidani M, Gay F, et al. Thalidomide for
treatment of multiple myeloma: 10 years
later. Blood. 2008;111(8):3968-77. 
23. Ludwig H, Durie BG, Bolejack V, Turesson
I, Kyle RA, Blade J, et al. Myeloma in
patients younger than age 50 years presents
with more favorable features and shows
better survival: an analysis of 10 549
patients from the International Myeloma
Working Group. Blood. 2008;111(8):4039-
47.
24. Vestal RE. Aging and pharmacology.
Cancer. 1997;80(7):1302-10. 
25. Yuen GJ. Altered pharmacokinetics in the
elderly. Clin Geriatr Med. 1990;6(2):257-67. 
26. Sotaniemi EA, Arranto AJ, Pelkonen O,
Pasanen M. Age and cytochrome P450-
linked drug metabolism in humans: an
analysis of 226 subjects with equal
histopathologic conditions. Clin Pharmacol
Ther. 1997;61(3):331-9.
27. Palumbo A, Anderson K. Multiple myelo-
ma. N Engl J Med. 2011;364(11):1046-60.
28. Liberati A. Need to realign patient-oriented
and commercial and academic research.
Lancet. 2011;378(9805):1777-8.
a. Palumbo et al.
94 haematologica | 2013; 98(1)
